martes, 31 de mayo de 2022

The immunogenicity and safety of the adjuvanted recombinant protein vaccine Sanofi/GSK-D614 or -B.1.351 administered as a heterologous booster dose

The immunogenicity and safety of the adjuvanted recombinant protein vaccine Sanofi/GSK-D614 or -B.1.351 administered as a heterologous booster dose
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)